Janux Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Janux Therapeutics R&D Spending Growth & History (JANX)
Janux Therapeutics's r&d spending was $125.9M for fiscal 2025.
View full Janux Therapeutics company overviewJanux Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $125.9M | $57.5M | +84.09% |
| 2024 | 2024-12-31 | $68.4M | $13.5M | +24.52% |
| 2023 | 2023-12-31 | $54.9M | $1.5M | +2.77% |
| 2022 | 2022-12-31 | $53.4M | $27.2M | +103.69% |
| 2021 | 2021-12-31 | $26.2M | $23.2M | +762.78% |
| 2020 | 2020-12-31 | $3.0M | — | — |
Janux Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $31.0M | −$3.7M | −10.59% |
| Q1 2026 | 2026-03-31 | $26.8M | $1.8M | +7.02% |
| Q4 2025 | 2025-12-31 | $31.5M | $10.7M | +51.63% |
| Q3 2025 | 2025-09-30 | $34.6M | $16.0M | +86.04% |
| Q2 2025 | 2025-06-30 | $34.7M | $19.8M | +132.68% |
| Q1 2025 | 2025-03-31 | $25.1M | $11.0M | +78.07% |
| Q4 2024 | 2024-12-31 | $20.8M | $8.6M | +69.97% |
| Q3 2024 | 2024-09-30 | $18.6M | $6.7M | +56.53% |
| Q2 2024 | 2024-06-30 | $14.9M | −$26,000 | −0.17% |
| Q1 2024 | 2024-03-31 | $14.1M | −$1.8M | −11.31% |
| Q4 2023 | 2023-12-31 | $12.2M | −$3.2M | −20.69% |
| Q3 2023 | 2023-09-30 | $11.9M | −$1.8M | −13.43% |
| Q2 2023 | 2023-06-30 | $14.9M | $838,000 | +5.95% |
| Q1 2023 | 2023-03-31 | $15.9M | $5.7M | +55.78% |
| Q4 2022 | 2022-12-31 | $15.4M | $4.3M | +38.19% |
| Q3 2022 | 2022-09-30 | $13.7M | $5.3M | +63.42% |
| Q2 2022 | 2022-06-30 | $14.1M | $9.3M | +197.36% |
| Q1 2022 | 2022-03-31 | $10.2M | $8.3M | +429.04% |
| Q4 2021 | 2021-12-31 | $11.2M | — | — |
| Q3 2021 | 2021-09-30 | $8.4M | $7.6M | +907.91% |
| Q2 2021 | 2021-06-30 | $4.7M | $4.1M | +603.86% |
| Q1 2021 | 2021-03-31 | $1.9M | — | — |
| Q3 2020 | 2020-09-30 | $834,000 | — | — |
| Q2 2020 | 2020-06-30 | $673,000 | — | — |
Janux Therapeutics r&d spending trends
Over the last five fiscal years, Janux Therapeutics's r&d spending increased from $3.0M to $125.9M, a change of $122.9M. The latest reported quarter, Q2 2026, shows $31.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Janux Therapeutics source filings ↗